Published in:
Open Access
01-12-2023 | Brachytherapy | Research
Comparison of two high dose rate intracavitary brachytherapy regimens in treatment of cervical cancer: a preliminary report
Authors:
Abhishek Krishna, AG Hasib, Donald Fernandes, M. S. Athiyamaan, Sandesh Rao, Sharaschandra Shankar, Mohsina Ali, Hepsiba Priyadarshini, Maria Sophia, CH Shridhar, Seby George, Amrutha Babu, Sourjya Banerjee, Johan Sunny, Challapalli Srinivas, Dilson Lobo
Published in:
Discover Oncology
|
Issue 1/2023
Login to get access
Abstract
Background
To assess and compare the local control and toxicities between HDR Intracavitary Brachytherapy with 7.5 Gy and 9 Gy per fraction after EBRT in treatment of carcinoma cervix.
Methodology
A total of 180 patients were randomly assigned to 2 arms. Arm A received HDR intracavitary brachytherapy with a dose of 7.5 Gy per fraction, 1 fraction per week for 3 fractions and Arm B received 9 Gy per fraction, 1 fraction per week for 2 fractions. Patients were evaluated on follow up for assessment of local control and toxicities.
Results
The median follow up was 12 months (6–18 months). In arm A 89% of the patient had complete response and 11% had recurrence or metastasis. In arm B 93% of the patient had complete response and 7% had recurrence or metastasis. Grade 2/3 diarrhoea was seen in 4.4% of patients in Arm A and in 7.7% in Arm B. Grade 2/3 proctitis was seen in 3.3% of patients in 7.5 Gy arm and in 6.6% in 9 Gy arm. One patient in each arm had grade 1 haematuria. The overall duration of treatment was significant lower in Arm B compared to Arm A (59 days vs 68 days, p = 0.01).
Conclusion
The result of this clinical study shows that Intracavitary brachytherapy with a dose of 9 Gy per fraction is non inferior to other schedules in term of local control and does not result in increased toxicity.